What’s the current market cap for Bicycle Therapeutics stock?

Bicycle Therapeutics (BCYC) has a market cap of $326M as of May 29, 2026.

What is the P/E ratio for Bicycle Therapeutics stock?

The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of May 29, 2026.

Does Bicycle Therapeutics stock pay dividends?

No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of May 29, 2026.

When is the next Bicycle Therapeutics dividend payment date?

Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.

What is the beta indicator for Bicycle Therapeutics?

Bicycle Therapeutics (BCYC) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Bicycle Therapeutics stock | $BCYC Share Price

13:30

09:10

04:45

00:25

20:00

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Ticker

$BCYC

Sector

Health

Primary listing

NASDAQ

Employees

288

Headquarters

Cambridge, United Kingdom

Website

www.bicycletherapeutics.com

BCYC Metrics

BasicAdvanced

$326m

-$3.16

1.56

What the Analysts think about BCYC

Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.

Bulls say / Bears say

Phase 2 data for nuzefatide pevedotin demonstrated a 40% confirmed overall response rate in EphA2-positive metastatic urothelial cancer and 100% in patients without previous MMAE treatment, with no Grade 3 or higher treatment-related adverse events, underscoring strong clinical potential (Reuters)

In March 2026, Bicycle shifted strategic focus to its next-generation pipeline, including nuzefatide pevedotin and Bicycle radioconjugates, improving resource allocation for high-potential programs (SEC)

Cash and cash equivalents of $559.5 million as of March 31, 2026, provide runway into 2030, supporting ongoing clinical development without immediate risk of dilution (StockTitan)

Collaboration revenue fell sharply to $0.9 million in Q1 2026 from $10.0 million a year ago after ending key partnerships with Genentech and Novartis, exposing a significant drop in external funding sources (Nasdaq)

Q1 2026 net loss totaled $60.8 million, or $0.87 per share, highlighting continued high operational expenses and extending the timeline to profitability (Nasdaq)

As part of its March 2026 strategic shift, Bicycle ended its Duravelo-3 and Duravelo-4 trials and cut its workforce by 30%, moves that could stall clinical progress and weaken the pipeline (SEC)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.

BCYC Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BCYC Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCYC

Capital at risk

Market closedADR

Upcoming events

No upcoming events

Bulls say / Bears say

Cash and cash equivalents of $559.5 million as of March 31, 2026, provide runway into 2030, supporting ongoing clinical development without immediate risk of dilution (StockTitan)

Q1 2026 net loss totaled $60.8 million, or $0.87 per share, highlighting continued high operational expenses and extending the timeline to profitability (Nasdaq)

As part of its March 2026 strategic shift, Bicycle ended its Duravelo-3 and Duravelo-4 trials and cut its workforce by 30%, moves that could stall clinical progress and weaken the pipeline (SEC)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.